Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma

16 Oct 2015

Abstract excerpt

PURPOSE: Dedifferentiated liposarcoma (DDLPS) is an aggressive malignancy that can recur locally or disseminate even after multidisciplinary care. Genetically amplified and expressed MDM2, often referred to as a "hallmark" of DDLPS, mostly sustains a wild-type p53 genotype, substantiating the MDM2:p53 axis as a potential therapeutic target for DDLPS. Here, we report on the preclinical effects of SAR405838, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Hippo pathway signaling and YAP/TAZ
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26475335
DOI: 10.1158/1078-0432.ccr-15-1522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaPMID 26475335Read ↗

Targeting the MDM2-p53 pathway in dedifferentiated liposarcomaSemantic proximity Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingSemantic proximity Read ↗

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaSemantic proximity Read ↗

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response PathwaySemantic proximity Read ↗

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.Semantic proximity Read ↗

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy SelectionSemantic proximity Read ↗

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.Semantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversSemantic proximity Read ↗

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.